SNDX as reported
Syndax Pharmaceuticals, Inc. reported $217M of revenue over the trailing twelve months, +397% on the year before. 9 reported series are charted on this page, each one as filed.
$217M
Revenue, trailing twelve months · to Q1 2026 · +397% against the twelve months before
- Net Income
- −$243M
Net Income · −27% year on year · trailing twelve months to Q1 2026
- Op Margin
- −113%
Op Margin · trailing twelve months to Q1 2026
- EPS
- −$2.79
EPS · −28% year on year · trailing twelve months to Q1 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $217M | +397% | Q1 2026 |
| Net Income | −$243M | −27% | Q1 2026 |
| EPS | −$2.79 | −28% | Q1 2026 |
| Op Margin | −113% | n/a | Q1 2026 |
| Net Margin | −122% | n/a | Q1 2026 |
| ROE | −377% | n/a | Q1 2026 |
| ROA | −55% | n/a | Q1 2026 |
| ROIC | −1507% | n/a | Q1 2026 |
| Free Cash Flow | −$69M | n/a | Q4 2018 · 29 quarters behind |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Syndax Pharmaceuticals, Inc. (SNDX) - Revenue & ProfitRevenue & ProfitSyndax Pharmaceuticals, Inc. (SNDX)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com